CL2015000532A1 - Molécula de enlace a interleuquina 18 (il-18); anticuerpo; polinucleótido que lo codifica; vector; célula huésped; composición farmacéutica; uso para tratar sarcoidosis y otras inmunodeficiencias; y kit de diagnóstico. - Google Patents
Molécula de enlace a interleuquina 18 (il-18); anticuerpo; polinucleótido que lo codifica; vector; célula huésped; composición farmacéutica; uso para tratar sarcoidosis y otras inmunodeficiencias; y kit de diagnóstico.Info
- Publication number
- CL2015000532A1 CL2015000532A1 CL2015000532A CL2015000532A CL2015000532A1 CL 2015000532 A1 CL2015000532 A1 CL 2015000532A1 CL 2015000532 A CL2015000532 A CL 2015000532A CL 2015000532 A CL2015000532 A CL 2015000532A CL 2015000532 A1 CL2015000532 A1 CL 2015000532A1
- Authority
- CL
- Chile
- Prior art keywords
- immunodeficiencies
- interleukin
- antibody
- vector
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Otolaryngology (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261697981P | 2012-09-07 | 2012-09-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015000532A1 true CL2015000532A1 (es) | 2015-06-05 |
Family
ID=49596347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015000532A CL2015000532A1 (es) | 2012-09-07 | 2015-03-04 | Molécula de enlace a interleuquina 18 (il-18); anticuerpo; polinucleótido que lo codifica; vector; célula huésped; composición farmacéutica; uso para tratar sarcoidosis y otras inmunodeficiencias; y kit de diagnóstico. |
Country Status (41)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200308A1 (ar) * | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
| JP6820743B2 (ja) * | 2013-09-05 | 2021-01-27 | エイビー２ バイオ ソシエテアノニム | 炎症性疾患におけるｉｌ−１８結合タンパク質（ｉｌ−１８ｂｐ） |
| WO2016020791A1 (en) | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
| KR102511343B1 (ko) | 2015-03-05 | 2023-03-17 | 에이비2 바이오 에스에이 | 염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ) 및 항체 |
| WO2017076805A1 (en) * | 2015-11-02 | 2017-05-11 | Glaxosmithkline Intellectual Property Development Limited | Use of an inhibitor of il18 for treatment of acute kidney injury |
| AU2016348391A1 (en) * | 2015-11-03 | 2018-05-17 | Janssen Biotech, Inc. | Antibodies specifically binding TIM-3 and their uses |
| CN108218978B (zh) * | 2016-12-13 | 2020-05-12 | 沈阳何氏眼产业集团有限公司 | 一种重组白细胞介素18及其制备方法与应用 |
| AU2018232883A1 (en) | 2017-03-09 | 2019-09-19 | Mab Discovery Gmbh | Antibodies specifically binding to human IL-1 R7 |
| UY37758A (es) | 2017-06-12 | 2019-01-31 | Novartis Ag | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos |
| CA3080492A1 (en) * | 2017-09-06 | 2019-03-14 | Yale University | Interleukin-18 variants and methods of use |
| WO2019213686A1 (en) * | 2018-05-10 | 2019-11-14 | The Council Of The Queensland Institute Of Medical Research | Therapeutic compositions and uses therefor |
| WO2020116423A1 (ja) | 2018-12-03 | 2020-06-11 | 株式会社ｍＡｂＰｒｏｔｅｉｎ | 活性型インターロイキン－１８タンパク質のネオエピトープを認識する抗体、及びその応用 |
| CN109870570A (zh) * | 2018-12-29 | 2019-06-11 | 广东云天抗体生物科技有限公司 | 一种检测猴il-18的酶联免疫试剂盒 |
| TW202233675A (zh) | 2020-10-29 | 2022-09-01 | 瑞士商諾華公司 | Ｉｌ－１８拮抗劑用於治療和／或預防異位性皮炎或相關病症之用途 |
| WO2022221264A1 (en) * | 2021-04-12 | 2022-10-20 | Ethos Biosciences, Inc. | Methods and compositions for analysis of acute kidney injury |
| CA3219360A1 (en) | 2021-06-22 | 2022-12-29 | Novartis Ag | Bispecific antibodies for use in treatment of hidradenitis suppurativa |
| JPWO2023286694A1 (es) | 2021-07-13 | 2023-01-19 | ||
| CN117177999A (zh) * | 2022-01-14 | 2023-12-05 | 和径医药科技（上海）有限公司 | 一种靶向IL-18Rβ的抗体及其应用 |
| WO2023178192A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
| WO2023209568A1 (en) * | 2022-04-26 | 2023-11-02 | Novartis Ag | Multispecific antibodies targeting il-13 and il-18 |
Family Cites Families (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| WO1988009344A1 (en) | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Targeted multifunctional proteins |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| JPH03230220A (ja) | 1990-02-05 | 1991-10-14 | Seiko Epson Corp | ソート処理方法 |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69233782D1 (de) | 1991-12-02 | 2010-05-20 | Medical Res Council | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
| AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
| JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| RU2139092C1 (ru) | 1993-06-03 | 1999-10-10 | Терапьютик Антибодиз Инк. | Фрагменты антител в терапии |
| EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| TW464656B (en) | 1994-11-15 | 2001-11-21 | Hayashibara Biochem Lab | Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| JP2009047705A (ja) | 1996-07-31 | 2009-03-05 | Hayashibara Biochem Lab Inc | 生物学的試料の検出方法 |
| JP2007121310A (ja) | 1996-07-31 | 2007-05-17 | Hayashibara Biochem Lab Inc | 自己免疫疾患診断剤 |
| US7141393B2 (en) | 1996-12-26 | 2006-11-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18-receptor proteins |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| EP1047781B1 (en) | 1998-01-23 | 2004-07-28 | Immunex Corporation | Il-18 receptors |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| CA2276216A1 (en) | 1998-06-24 | 1999-12-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | An artificial peptide capable of neutralizing the biological activity of interleukin-18 |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
| AR022952A1 (es) | 1999-03-19 | 2002-09-04 | Smithkline Beecham Corp | ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL |
| ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| US6432678B1 (en) | 1999-06-21 | 2002-08-13 | Smithkline Beecham Corporation | Macaca cynomolgus IL 18 |
| DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
| IL142025A0 (en) | 1999-07-20 | 2002-03-10 | Morphosys Ag | Novel methods for displaying (poly) peptides/proteins on bacteriophage particles via disulfide bonds |
| ES2282133T3 (es) | 1999-08-24 | 2007-10-16 | Medarex, Inc. | Anticuerpos frente a la ctla-4 humano y sus usos. |
| JP3230220B2 (ja) | 1999-10-07 | 2001-11-19 | 独立行政法人 農業技術研究機構 | ブタ由来インターロイキン−１８に対するモノクローナル抗体 |
| CA2324168A1 (en) | 1999-11-16 | 2001-05-16 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Antibody specific to interleukin 18 precursor |
| TWI373343B (en) | 2000-02-10 | 2012-10-01 | Abbott Gmbh & Co Kg | Antibodies that bind human interleukin-18 and methods of making and using |
| CN101062415A (zh) * | 2000-02-21 | 2007-10-31 | 应用研究系统Ars股份公司 | Il－18抑制剂的应用 |
| ME00554B (me) | 2000-05-05 | 2012-03-20 | Serono Lab | KORIŠĆENJE IL-18 INHIBITORA ZA LIJEČENJE l/ILI PREVENCIJU ATEROSKLEROZE |
| DE60139720D1 (de) | 2000-06-28 | 2009-10-08 | Glycofi Inc | Verfahren für die Herstellung modifizierter Glykoproteine |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| WO2002032374A2 (en) | 2000-10-18 | 2002-04-25 | Immunex Corporation | Methods for treating il-18 mediated disorders |
| CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| EA010180B1 (ru) | 2001-01-29 | 2008-06-30 | Лаборатуар Сероно Са | Применение ингибитора il-18 для приготовления лекарственного средства для лечения и/или профилактики кардиомиопатии |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
| US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| CN100423777C (zh) | 2001-10-25 | 2008-10-08 | 杰南技术公司 | 糖蛋白组合物 |
| US20040023336A1 (en) | 2001-10-26 | 2004-02-05 | Heavner George A. | Mut-IL-18 or Mut-IL-18R proteins, antibodies, compositions, methods and uses |
| PT1487541E (pt) | 2002-03-22 | 2008-12-10 | Inst Nat Sante Rech Med | Utilização de inibidores de il-8 para o tratamento e/ou prevenção de doenças vasculares periféricas |
| FR2838444B1 (fr) | 2002-04-10 | 2016-01-01 | Neovacs | Nouveaux peptides et leur application en therapeutique |
| AU2004235595C1 (en) | 2003-04-30 | 2009-09-24 | Japan Science And Technology Agency | Human antihuman interleukin-18 antibody, fragment thereof and method of using the same |
| SI1622939T1 (sl) | 2003-05-13 | 2012-06-29 | Merck Serono Sa | Akrivne variante il-18 vezavnega proteina in medicinske uporabe le-tega |
| DE10324447A1 (de) | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin |
| ATE414106T1 (de) | 2003-06-30 | 2008-11-15 | Domantis Ltd | Pegylierte single-domain-antikörper (dab) |
| JP2005052021A (ja) | 2003-08-07 | 2005-03-03 | Yokohama City | インターロイキン−１８変異体タンパク質 |
| US20050075702A1 (en) | 2003-10-01 | 2005-04-07 | Medtronic, Inc. | Device and method for inhibiting release of pro-inflammatory mediator |
| US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
| US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| WO2005075648A1 (en) | 2004-01-28 | 2005-08-18 | Gifu University | Interleukin-18 mutant proteins |
| EP1744734A2 (en) | 2004-02-20 | 2007-01-24 | Novo Nordisk A/S | Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds |
| WO2005097998A2 (en) | 2004-03-31 | 2005-10-20 | Regeneron Pharmaceuticals, Inc. | Il-18 specific polypeptides and therapeutic uses thereof |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| JP4673068B2 (ja) | 2005-01-19 | 2011-04-20 | 独立行政法人科学技術振興機構 | Ｔｈ１型アレルギー疾患治療用組成物 |
| WO2007005426A2 (en) | 2005-06-29 | 2007-01-11 | Rules-Based Medicine, Inc. | Methods and kits for the diagnosis of acute coronary syndrome |
| US20090215992A1 (en) | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
| EP1928506A4 (en) | 2005-08-19 | 2009-10-21 | Abbott Lab | IMMUNOGLOBULIN HAVING TWO VARIABLE DOMAINS AND USES THEREOF |
| EP3611266B1 (en) | 2005-08-23 | 2022-11-09 | The Trustees of the University of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
| JP4728785B2 (ja) | 2005-11-30 | 2011-07-20 | 独立行政法人科学技術振興機構 | Ｉｌ−１８の生物活性を有する新規ポリペプチドの生産方法、および当該ポリペプチドの産生を阻害する物質のスクリーニング方法 |
| NZ572565A (en) | 2006-05-25 | 2011-04-29 | Glaxo Group Ltd | Modified humanised anti-interleukin-18 antibodies |
| EP3492488A1 (en) | 2007-08-22 | 2019-06-05 | The Regents of The University of California | Activatable binding polypeptides and methods of identification and use thereof |
| MX2010008364A (es) | 2008-01-30 | 2010-08-23 | Abbott Lab | Composiciones y metodos para cristalizar fragmentos de anticuerpo. |
| US9109026B2 (en) | 2008-06-03 | 2015-08-18 | Abbvie, Inc. | Dual variable domain immunoglobulins and uses thereof |
| KR20110031369A (ko) | 2008-07-08 | 2011-03-25 | 아보트 러보러터리즈 | 프로스타글란딘 ｅ2 이원 가변 도메인 면역글로불린 및 이의 용도 |
| EP2326315A1 (en) | 2008-08-18 | 2011-06-01 | Glaxo Group Limited | Treatment of an autoimmune disease using il-18 antagonists |
| WO2010040736A2 (en) | 2008-10-07 | 2010-04-15 | Ablynx Nv | Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling |
| CN104974251A (zh) | 2008-10-20 | 2015-10-14 | Abbvie公司 | 在抗体纯化过程中的病毒灭活 |
| NZ592094A (en) | 2008-10-20 | 2013-01-25 | Abbott Lab | Antibodies that bind to il-18 and methods of purifying the same |
| US20120116978A1 (en) | 2008-12-23 | 2012-05-10 | Mtn Mobile Money Sa (Pty) Ltd | Method of and system for securely processing a transaction |
| CN102458459A (zh) | 2009-05-01 | 2012-05-16 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
| SG182783A1 (en) | 2010-02-09 | 2012-09-27 | Glaxo Group Ltd | Treatment of a metabolic disorder |
| CA2822515C (en) * | 2010-12-20 | 2023-04-25 | Medimmune Limited | Anti-il-18 antibodies and their uses |
| JOP20200308A1 (ar) * | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
| UY37758A (es) * | 2017-06-12 | 2019-01-31 | Novartis Ag | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos |
-
2012
- 2012-09-07 JO JOP/2020/0308A patent/JOP20200308A1/ar unknown
-
2013
- 2013-09-04 US US14/017,561 patent/US9376489B2/en active Active
- 2013-09-05 RS RS20200663A patent/RS60394B1/sr unknown
- 2013-09-05 MX MX2015002986A patent/MX2015002986A/es active IP Right Grant
- 2013-09-05 AP AP2015008266A patent/AP2015008266A0/xx unknown
- 2013-09-05 SG SG10201706623WA patent/SG10201706623WA/en unknown
- 2013-09-05 BR BR112015004783-1A patent/BR112015004783B1/pt active IP Right Grant
- 2013-09-05 JP JP2015530535A patent/JP6404817B2/ja active Active
- 2013-09-05 EA EA201992614A patent/EA201992614A3/ru unknown
- 2013-09-05 SI SI201331738T patent/SI2892923T1/sl unknown
- 2013-09-05 KR KR1020217001854A patent/KR102330653B1/ko active IP Right Grant
- 2013-09-05 PL PL13792452T patent/PL2892923T3/pl unknown
- 2013-09-05 PT PT137924528T patent/PT2892923T/pt unknown
- 2013-09-05 CA CA2883821A patent/CA2883821C/en active Active
- 2013-09-05 CN CN201380046530.3A patent/CN104640879B/zh active Active
- 2013-09-05 AU AU2013311234A patent/AU2013311234A1/en not_active Abandoned
- 2013-09-05 PE PE2015000304A patent/PE20150649A1/es active IP Right Grant
- 2013-09-05 DK DK13792452.8T patent/DK2892923T3/da active
- 2013-09-05 EA EA201590523A patent/EA034610B1/ru not_active IP Right Cessation
- 2013-09-05 EP EP20157418.3A patent/EP3725805A1/en active Pending
- 2013-09-05 EP EP13792452.8A patent/EP2892923B1/en active Active
- 2013-09-05 LT LTEP13792452.8T patent/LT2892923T/lt unknown
- 2013-09-05 HU HUE13792452A patent/HUE050464T2/hu unknown
- 2013-09-05 SG SG11201501559VA patent/SG11201501559VA/en unknown
- 2013-09-05 MA MA37892A patent/MA37892A1/fr unknown
- 2013-09-05 ES ES13792452T patent/ES2804704T3/es active Active
- 2013-09-05 WO PCT/IB2013/058317 patent/WO2014037899A2/en active Application Filing
- 2013-09-05 MY MYPI2015700574A patent/MY174691A/en unknown
- 2013-09-05 KR KR1020157008513A patent/KR102207672B1/ko active IP Right Grant
- 2013-09-05 BR BR122019028128-9A patent/BR122019028128B1/pt active IP Right Grant
- 2013-09-05 JO JOP/2013/0269A patent/JO3764B1/ar active
- 2013-09-05 CN CN201811364662.1A patent/CN109517065B/zh active Active
- 2013-09-06 TW TW102132287A patent/TWI613217B/zh active
- 2013-09-06 UY UY0001035016A patent/UY35016A/es not_active Application Discontinuation
- 2013-09-06 AR ARP130103173A patent/AR092465A1/es unknown
- 2013-09-06 TW TW106136512A patent/TWI655208B/zh active
-
2015
- 2015-02-09 IL IL237161A patent/IL237161B/en active IP Right Grant
- 2015-02-10 ZA ZA2015/00954A patent/ZA201500954B/en unknown
- 2015-02-19 TN TNP2015000057A patent/TN2015000057A1/fr unknown
- 2015-03-04 CL CL2015000532A patent/CL2015000532A1/es unknown
- 2015-03-04 PH PH12015500466A patent/PH12015500466A1/en unknown
- 2015-03-06 GT GT201500054A patent/GT201500054A/es unknown
- 2015-03-06 CR CR20150121A patent/CR20150121A/es unknown
- 2015-03-06 CO CO15052159A patent/CO7400884A2/es unknown
- 2015-03-06 MX MX2020007022A patent/MX2020007022A/es unknown
- 2015-03-06 CU CUP2015000022A patent/CU24249B1/es unknown
- 2015-04-06 EC ECIEPI201513209A patent/ECSP15013209A/es unknown
- 2015-10-06 HK HK15109750.4A patent/HK1209136A1/xx unknown
-
2016
- 2016-03-18 AU AU2016201741A patent/AU2016201741B2/en active Active
- 2016-05-25 US US15/164,508 patent/US10081677B2/en active Active
-
2017
- 2017-12-06 AU AU2017272201A patent/AU2017272201B2/en active Active
-
2018
- 2018-08-24 US US16/111,659 patent/US11111293B2/en active Active
- 2018-09-12 JP JP2018170754A patent/JP2019037230A/ja active Pending
-
2019
- 2019-07-29 IL IL268336A patent/IL268336B/en unknown
- 2019-12-27 JP JP2019238049A patent/JP6944509B2/ja active Active
-
2020
- 2020-03-03 AU AU2020201556A patent/AU2020201556B2/en active Active
- 2020-06-05 HR HRP20200906TT patent/HRP20200906T1/hr unknown
- 2020-06-24 CY CY20201100582T patent/CY1123071T1/el unknown
-
2021
- 2021-07-27 US US17/386,429 patent/US20220098296A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015000532A1 (es) | Molécula de enlace a interleuquina 18 (il-18); anticuerpo; polinucleótido que lo codifica; vector; célula huésped; composición farmacéutica; uso para tratar sarcoidosis y otras inmunodeficiencias; y kit de diagnóstico. | |
| EA201400579A1 (ru) | Антитела к il-36r | |
| CL2015000420A1 (es) | Anticuerpo de unión a gfr alfa 3 (gfra3); ácido nucleico que lo codifica; vector; método para producirlo; composición farmacéutica que lo comprende; y uso para tratar una afección o enfermedad relacionada con gfra3. | |
| HK1205201A1 (en) | Proteins comprising mrsa pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat mrsa infections mrsa pbp2a mrsa | |
| EA201401204A1 (ru) | Антитела к il-23p19 | |
| PH12015502553A1 (en) | Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof | |
| EA201300530A1 (ru) | Антитела к il-23 | |
| EA201600338A1 (ru) | Биспецифическая связывающая молекула, связывающаяся с vegf и ang2 | |
| CL2014002348A1 (es) | Compuestos derivados de fenicol; composicion farmaceutica que los comprende; y su uso para controlar o tratar infecciones bacterianas en ganado. | |
| DK2657333T3 (da) | Porcint circovirus type 2, immunsammensætning indeholdende samme, assaykit og anvendelse deraf | |
| CO6791606A2 (es) | Composiciones y métodos para el tratamiento en aplicaciones clínicas de amplio espectro, no diferenciadas o combinadas | |
| IL237345A0 (en) | Antibody and drug conjugates (adc) that bind to 158p1d7 proteins, preparations containing them and their uses | |
| IL221205A (en) | Antibody Couplings Binding to B10F2P161 Proteins Containing and Using Them | |
| BR112012005338A2 (pt) | anticorpos humanos de afinidade alta para receptor-2 ativado por protease humana. | |
| ECSP14020402A (es) | Polipéptidos de unión a cx3cr1 | |
| DK2877019T3 (da) | Sikkerede herbisidiske sammensætninger til anvendelse i ris | |
| BR112014031412A2 (pt) | método de preparação de uma composição, composição e seu uso, e kit. | |
| CL2015000709A1 (es) | Polipéptido de unión il-17a glicosilada; construcción de fusión; molécula de ácido nucleico que codifica al polipéptido; composición de diagnóstico o farmacéutica para tratar enfermedad inflamatoria, autoinmune y/o relacionada a la pérdida ósea. | |
| PH12015501687A1 (en) | Novel binding proteins from pcsk9 | |
| CL2014003339A1 (es) | Anticuerpo humanizado anti-trka con propiedades inhibitorias mejoradas; composición que lo comprende; y uso para tratar el dolor. | |
| FR2987741B1 (fr) | Kit comprenant deux compositions separees, notamment pour une application cosmetique | |
| CL2014003167A1 (es) | Molécula de unión que se une específicamente a inteleuquina 6 (il-6); composición farmacéutica que la comprende; ácido nucleico; vector; célula huésped; y uso para tratar enfermedad o trastorno asociado a il-6. | |
| CL2013001324A1 (es) | Kit que comprende ec145 y uno o mas agentes quimioterapéuticos adicionales; uso para tratar un cancer. | |
| DK2745849T3 (da) | Polydeoxyribonukleotidsammensætning og anvendelser deraf | |
| FR2962042B1 (fr) | Composition cosmetique comprenant du copa. |